AstraZeneca is conducting a phase 3 trial on its Breztri Aerosphere inhaler therapy for COPD patients with elevated cardiopulmonary risk. The therapy combines budesonide, glycopyrrolate, and formoterol fumarate and is approved for COPD maintenance treatment by the FDA. The THARROS trial aims to assess its efficacy in reducing severe cardiopulmonary events in COPD patients at risk. Study participants must have cardiovascular disease or risk factors. The trial is expected to provide important evidence on the therapy’s potential to improve outcomes in COPD. A second trial, ATHLOS, is also evaluating Breztri Aerosphere on cardiopulmonary parameters in COPD patients.
Source link
THARROS Trial Will Assess Breztri on Cardiopulmonary Outcomes in COPD Patients –
